IPOPI releases statement on access to IG Therapies
This new IPOPI statement is intended to provide a summary of IPOPI’s position with regards to the importance of ensuring access for patients living with a primary immunodeficiency (PID) to the best suited immunoglobulin (IG) replacement therapy, as selected and prescribed by their physician.
IPOPI is concerned by recent developments in several countries that may restrict access to the best suited IG therapy for individual patients. To access the statement click here
Registration No. 1058005